The Precision Peptide Company Receivables

The Precision Peptide Company posts a receivables of $96K as of July 2026. That compares with $55K in the prior-year period — up 74.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, The Precision Peptide Company's receivables was $55K. The latest reading is $96K — a 74.2% year-over-year increase (period ending July 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of The Precision Peptide Company's financial statement story. At $96K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PNGAF's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; The Precision Peptide Company's other metric pages and overview cover the third.